GlassScriptPhysician profile
Morgan A Spurlock
NPI 1982133559
$4,832.46
in general payments reported to CMS, 2019-2025
39 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $212 · 2021: $893 · 2022: $842 · 2023: $836 · 2024: $1,029 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,106.66 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $958.87 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $398.83 | 2020-2025 | |
| Amgen INC. | $378.20 | 2020-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $206.66 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $169.12 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $153.18 | 2022-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Sanofi-Aventis U.S. LLC | $133.98 | 2020-2025 | |
| Lundbeck LLC | $116.29 | 2023-2024 | Rexulti, Vyepti |
| Dexcom, INC. | $116.04 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $100.34 | 2020-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $97.64 | 2021 | |
| Amarin Pharma, INC. | $92.61 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.35 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $59.47 | 2024-2025 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Spurlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.